EMA/699482/2021

# European Medicines Agency decision

P/0535/2021

of 6 December 2021

on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven), (EMEA-001261-PIP01-11-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0535/2021

of 6 December 2021

on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven), (EMEA-001261-PIP01-11-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0023/2013 issued on 25 February 2013, the decision P/0109/2014 issued on 5 May 2014, the decision P/0136/2015 issued on 15 June 2015, the decision P/0330/2016 issued on 2 December 2016, the decision P/0264/2018 issued on 15 August 2018 and the decision P/0040/2021 issued on 27 January 2021,

Having regard to the application submitted by Eisai GmbH on 5 August 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and proposing a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for eribulin (Halaven), solution for injection, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices..

***Article 2***

A waiver for eribulin (Halaven), solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

***Article 3***

This decision is addressed to Eisai GmbH, 3 Edmund-Rumpler-Straße, 60549 - Frankfurt am Main, Germany.

EMA/PDCO/483779/2021
Amsterdam, 12 November 2021

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001261-PIP01-11-M07

## Scope of the application

**Active substance(s):**

Eribulin

**Invented name:**

Halaven

**Condition(s):**

Treatment of soft tissue sarcoma

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Intravenous use

**Name/corporate name of the PIP applicant:**

Eisai GmbH

**Information about the authorised medicinal product:**

See Annex II

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eisai GmbH submitted to the European Medicines Agency on 5 August 2021 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0023/2013 issued on 25 February 2013, the decision P/0109/2014 issued on 5 May 2014, the decision P/0136/2015 issued on 15 June 2015, the decision P/0330/2016 issued on 2 December 2016, the decision P/0264/2018 issued on 15 August 2018 and the decision P/0040/2021 issued on 27 January 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and proposed a waiver.

The procedure started on 14 September 2021.

## Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A waiver for a new paediatric subset has been added.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion and to the deferral in the scope set out in the Annex I of this opinion;
   - to grant a waiver for one or more subsets of the paediatric population concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

# 1. Waiver

## *1.1. Condition:*

Treatment of soft tissue sarcoma

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- solution for injection, intravenous use;
- on the grounds that the specific medicinal product is likely to be ineffective.

# 2. Paediatric Investigation Plan

## *2.1. Condition*

Treatment of soft tissue sarcoma

### 2.1.1. Indication(s) targeted by the PIP

Treatment of rhabdomyosarcoma

Treatment of non-rhabdomyosarcoma soft tissue sarcoma

Treatment of Ewing sarcoma

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Solution for injection

### 2.1.4. Measures

| Area | Number of measures | Description |
|---|---|---|
| Quality-related measures | 0 | Not applicable |
| Non-clinical measures | 4 | **Study 1 (PPC-2012-02n)**<br>In vitro sensitivity of 23 human paediatric tumour cell lines to inhibition of proliferation by eribulin<br>**Study 2 (PPC-2012-02n)**<br>Antitumor activity of eribulin in human paediatric tumour xenografts in athymic mice |

| | | |
|---|---|---|
| | | **Study 3 (PPTP Stage 2)**<br>Dose-response and Ewing sarcoma testing<br>**Study 4**<br>Human RMS tumour xenograft study with eribulin plus irinotecan |
| Clinical measures | 3 | **Study 5 (E7389-A001-113)**<br>Dose escalation study to assess maximum tolerated dose (MTD), safety and tolerability of eribulin in paediatric patients at least 6 months of age with soft tissue sarcoma<br>**Study 6 (E7389-G000-213)**<br>Open-label, single arm study to assess safety and efficacy of eribulin in combination with irinotecan in paediatric patients at least 6 months of age with relapsed/refractory soft tissue sarcoma<br>**Study 7 (E7389-G000-214)** (study removed in procedure EMEA-001261-PIP01-11-M07)<br>**Study 8** (**E7389-G000-223)** (study added in procedure EMEA-001261-PIP01-11-M05)<br>Open-label, uncontrolled, multicentre trial to evaluate safety and preliminary activity of eribulin in children from 12 months to less than 18 years of age with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS) |

# 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By September 2021 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |

# Annex II

# Information about the authorised medicinal product

## Condition(s) and authorised indication(s):

1. Treatment of breast cancer

Authorised indication(s):

- Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

2. Treatment of soft tissue sarcoma

Authorised indication(s):

- Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

## Authorised pharmaceutical form(s):

Solution for injection

## Authorised route(s) of administration:

Intravenous use